Blood pressure lowering tripeptides derived from milk protein;Blutdrucksenkende tripeptide aus der milch

Therapeutische Umschau

Volumn 64, Issue 3, 2007, Pages 177-179

  Nussberger, Jürg ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CASEIN; CASOKININE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ISOLEUCYLPROLYLPROLINE; MILK PROTEIN; PROTEINASE; TRIPEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VALYLPROLYLPROLINE;

ASPERGILLUS ORYZAE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIETARY INTAKE; DRUG ISOLATION; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME INHIBITION; FERMENTATION; FRUIT; HUMAN; HYDROLYSIS; HYPERTENSION; LACTOBACILLUS HELVETICUS; LIFESTYLE MODIFICATION; PROPHYLAXIS; SHORT SURVEY; VEGETABLE;

DIETARY SUPPLEMENTS; HUMANS; HYPERTENSION; MILK PROTEINS; PEPTIDES;

EID: 33947253196     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.64.3.177     Document Type: Short Survey

References (23)

1. Ferreira SH. A bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca. Br J Pharmacol Chemother 1965; 24: 163-9.
2. Ferreira SH, Bartelt DC, Greene LJ. Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom. Biochemistry 1970; 9: 2583-93.
3. Collier JG, Robinson BF, Vane JR. Reduction of pressure effects of angotensin I in man by synthetic nonapeptide (B.P.P.9a or SQ 20,881) which inhibits converting enzyme. Lancet 1973; I: 72-4.
4. Gavras H, Brunner HR, Laragh JH, Sealey JE, Gavras I, Vukovich RA. An angiotensin converting enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med 1974; 291: 817-21.
5. Gavras H, Faxon DP, Berkoben J, Brunner HR, Ryan TJ. Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation 1979; 58: 770-6.
6. Nakamura Y, Yamamoto N, Sakai K, Okubo A, Yamazaki S, Takano T. Purification and characterization of angiotensin I - converting enzyme inhibitors from sour milk. J Dairy Sci 1995; 78: 777-83.
7. International Society of Hypertension. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
8. Schweizerische Hypertoniegesellschaft. Arterielle Hypertonie 2005. Empfehlungen für Ärzte, www.swisshypertension.ch
9. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents. Science 1977; 196: 441-4.
10. Nurminen ML. Milk-derived peptides and blood pressure. Bulletin Internat Dairy Federation 2000; 353: 11-5.
11. Lopez-Fandino R, Otte J, van Camp J. Physiological, chemical and technological aspects of milk-protein-derived peptides with antihypertensive and ACE-inhibitory activity. Internat Dairy J 2006; 16: 1277-93.
12. Hata Y, Yamamoto M, Ohni M, Nakajima K, Nakamura Y, Takano T. A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. Am J Clin Nutr 1996; 64: 767-71.
13. Mizushima S, Ohshige K, Watanabe J, Kimura M, Kadowaki T, Nakamura Y, et al. Randomized controlled trial of sour milk on blood pressure in borderline hypertensive men. Am J Hypertens 2004; 17: 701-6.
14. Mizuno S, Matsuura K, Gotou T, Nishimura S, Kajimoto O, Yabune M, et al. Antihypertensive effect of casein hydrolysate in a placebo-controlled study in subjects with high-normal blood pressure and mild hypertension. Brit J Nutr 2005; 94: 84-91.
15. Sano J, Ohki K, Higuchi T, Aihara K, Mizuno S, Kajimoto O, et al. Effect of casein hydrolysate, prepared with protease derived from Aspergillus oryzae, on subjects with high-normal blood pressure or mild hypertension. J Med Food 2005; 8: 423-30.
16. Seppo L, Kerojoki O, Suomalainen T, Korpela R. The effect of a Lactobacillus helveticus LBK-16H fermented milk on hypertension: A pilot study on humans. Milchwirtschaft 2002; 57: 124-7.
17. Seppo L, Jauhiainen T, Poussa T, Korpela R. A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Am J Clin Nutr 2003; 77: 326-30.
18. Tuomilehto J, Lindström J, Hyyrynen J, Korpela R, Karhunen ML, Mikkola L, et al. Effect of ingesting sour milk fermented using Lactobacillus helveticus bacteria producing tripeptides on blood pressure in subjects with mild hypertension. J Human Hypertens 2004; 18: 795-802.
19. Jauhiainen T, Verpaatalo H, Poussa T, Kyrönpalo S, Rasmussen M, Korpela R. Lactobacillus helveticus fermented milk lowers blood pressure in hypertensive subjects in 24-h ambulatory blood pressure measurement. Am J Hypertens 2005; 18: 1600-5.
20. Nakamura Y, Yamamoto N, Sakai K, Okubo A, Yamazaki S, Takano T. Purification and characterization of angiotensin I - converting enzyma inhibitors from sour milk. J Dairy Sci 1995; 78: 777-83.
21. Meisel H, Goepfert A, Günther S. ACE-inhibitory activities in milk products. Milchwissenschaft 1997; 52: 307-11.
22. Sipola M, Finckenberg P, Korpela R, Verpaatalo H, Nurminen ML. Effect of long-term intake of milk products on blood pressure in hypertensive rats. J Dairy Res 2002; 69: 103-11.
23. Bernhard BK, Nakamura Y, Bando I, Mennear JH, Maeono M, Mizuno S, et al. Studies of the the toxicological potential of tripeptides (L-valyl-L-prolyl-L- proline and L-isoleucyl-L-prolyl-L-proline). Int J Toxicol 2005; 24 (Suppl 4): 1-113.